Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Artificial intelligence for drug discovery and development in Alzheimer's disease

8 Feb 2024

Abstract excerpt

The complex molecular mechanism and pathophysiology of Alzheimer's disease (AD) limits the development of effective therapeutics or prevention strategies. Artificial Intelligence (AI)-guided drug discovery combined with genetics/multi-omics (genomics, epigenomics, transcriptomics, proteomics, and metabolomics) analysis contributes to the understanding of the pathophysiology and precision medicine of the disease,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bioinformatics and Genomic Networks
Share to Cholinesterase and Neurodegenerative Diseases
Share to Computational Drug Discovery Methods

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38335558
DOI: 10.1016/j.sbi.2024.102776

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Artificial intelligence for drug discovery and development in Alzheimer's diseasePMID 38335558Read ↗

Artificial intelligence for dementia genetics and omics.Semantic proximity Read ↗

AI-based mining of biomedical literature: Applications for drug repurposing for the treatment of dementiaSemantic proximity Read ↗

Exploring Advanced Applications of Artificial Intelligence in Neuropharmacology: A Comprehensive OverviewSemantic proximity Read ↗

Integrating GWAS and Transcriptomic Data Using PrediXcan and Multimodal Deep Learning Reveals Genetic Basis and Drug Repositioning Opportunities for Alzheimer’s DiseaseSemantic proximity Read ↗

Role of Artificial Intelligence in Modern Drug Discovery: A Literature OverviewSemantic proximity Read ↗

Recent Applications of Bioinformatics in Target Identification and Drug Discovery for Alzheimer’s DiseaseSemantic proximity Read ↗

Screening novel drug candidates for Alzheimer’s disease by an integrated network and transcriptome analysisSemantic proximity Read ↗

AI-based mining of biomedical literature: Applications for drug repurposing for the treatment of dementiaSemantic proximity Read ↗

DeepDrug: An Expert-led Domain-specific AI-Driven Drug-Repurposing Mechanism for Selecting the Lead Combination of Drugs for Alzheimer’s DiseaseSemantic proximity Read ↗

Machine Learning Identifies Novel Candidates for Drug Repurposing in Alzheimer’s DiseaseSemantic proximity Read ↗

Leveraging Generative AI to Prioritize Drug Repurposing Candidates: Validating Identified Candidates for Alzheimer’s Disease in Real-World Clinical DatasetsSemantic proximity Read ↗

Multi-omics and Artificial Intelligence technology for elucidating disease pathophysiology.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.